Search research articles
Contact Us
Filters
Showing results (61-70 of 77) with videos related to
Page
of 8
Sort By:
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Radiology
|
August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity
Christina Messiou, Matthew Orton, Joo Ern Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
Timothy A Yap, David Olmos, Andre T Brunetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
Udai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Lancet (London, England)
|
March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
The Lancet. Oncology
|
July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K Sandhu, William R Schelman, George Wilding, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
Timothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 11, 2020
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation
Emily C Bartlett, Samuel V Kemp, Carole A Ridge, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 77) with videos related to
Sort By:
Page
of 8
Molecular Cancer Therapeutics
|
April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation
Joo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Radiology
|
August 15, 2012
Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity
Christina Messiou, Matthew Orton, Joo Ern Ang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
Timothy A Yap, David Olmos, Andre T Brunetto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 25, 2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer
Udai Banerji, D Ross Camidge, Henk M W Verheul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors
David Olmos, Roger P A'hern, Silvia Marsoni, et al.
Lancet (London, England)
|
March 31, 2016
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study
Victor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
The Lancet. Oncology
|
July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K Sandhu, William R Schelman, George Wilding, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
Timothy A Yap, Hendrik-Tobias Arkenau, D Ross Camidge, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 11, 2020
Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation
Emily C Bartlett, Samuel V Kemp, Carole A Ridge, et al.
Page
of 8